{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:05:37Z","timestamp":1769821537562,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:p>This case report describes a pharmacokinetic drug\u2013drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir\/velpatasvir, a direct\u2010acting antiviral drug, leading to cardiac toxicity. A 75\u2010year\u2010old man, with no cardiovascular history but a diagnosis of metastatic nonsmall cell lung cancer with mesenchymal\u2013epithelial transition exon\u201014 deletion and hepatitis C virus infection genotype 1A, received both crizotinib and sofosbuvir\/velpatasvir. Crizotinib was well tolerated, but 1\u2009week after sofosbuvir\/velpatasvir initiation, the patient experienced bilateral lower\u2010limb oedema and class III New York Heart Association dyspnoea. We assumed that increased exposure to crizotinib could account for this cardiac toxicity. Drug causality was probable according to the Naranjo scale. We hypothesized a reciprocal interaction between crizotinib and velpatasvir, mediated by both cytochrome 3A4 (CYP3A4) and P\u2010glycoprotein (P\u2010gp). Clinicians should be aware of the risk of drug\u2013drug interactions between direct\u2010acting antiviral agents that inhibit CYP3A4 (glecaprevir) and\/or P\u2010gp (voxilaprevir, velpatasvir) and anticancer tyrosine kinase inhibitors that are mostly CYP3A4 and\/or P\u2010gp substrates (gefitinib, afatinib, erlotinib, crizotinib, ceritinib, lorlatinib, brigatinib, capmatinib etc.).<\/jats:p>","DOI":"10.1111\/bcp.15674","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T01:08:41Z","timestamp":1675040921000},"page":"1486-1490","source":"Crossref","is-referenced-by-count":5,"title":["Cardiac toxicity associated with pharmacokinetic drug\u2013drug interaction between crizotinib and sofosbuvir\/velpatasvir: A case report"],"prefix":"10.1111","volume":"89","author":[{"given":"Anthia","family":"Monribot","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Cochin Hospital, AP\u2010HP, University of Paris  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Huillard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cochin Hospital, AP\u2010HP, Universit\u00e9 de Paris  Paris France"},{"name":"Sorbonne Paris Cite, Faculty of Medicine University of Paris Descartes  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8269-9817","authenticated-orcid":false,"given":"Nihel","family":"Khoudour","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Pharmacochemisty Cochin Hospital, AP\u2010HP, Paris, France; CARPEM  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3141-5925","authenticated-orcid":false,"given":"Laure\u2010H\u00e9l\u00e8ne","family":"Pr\u00e9ta","sequence":"additional","affiliation":[{"name":"Regional Center of Pharmacovigilance, Department of Pharmacology Cochin Hospital, AP\u2010HP, Paris, University of Paris  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Blanchet","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Pharmacochemisty Cochin Hospital, AP\u2010HP, Paris, France; CARPEM  Paris France"},{"name":"UMR8038 CNRS, U.1268 INSERM, Faculty of Pharmacy University Paris Descartes, PRES Sorbonne Paris Cit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Cabanes","sequence":"additional","affiliation":[{"name":"Department of Cardiology Cochin Hospital, AP\u2010HP, University of Paris  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Batista","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Cochin Hospital, AP\u2010HP, University of Paris  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Pallet","sequence":"additional","affiliation":[{"name":"Department of Biochemistry H\u00f4pital Europ\u00e9en Georges Pompidou, AP\u2010HP, Paris, France; University of Paris Descartes, INSERM U.1147  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-3571","authenticated-orcid":false,"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[{"name":"Regional Center of Pharmacovigilance, Department of Pharmacology Cochin Hospital, AP\u2010HP, Paris, University of Paris  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cochin Hospital, AP\u2010HP, Universit\u00e9 de Paris  Paris France"},{"name":"Sorbonne Paris Cite, Faculty of Medicine University of Paris Descartes  France"},{"name":"Cochin Institute, INSERM U.1016  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Sogni","sequence":"additional","affiliation":[{"name":"Department of Hepatology Cochin Hospital, AP\u2010HP, Paris, France; University of Paris Descartes, Sorbonne Paris Cit\u00e9  Paris France"},{"name":"Institut Pasteur, U.1223, INSERM  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-1478","authenticated-orcid":false,"given":"Audrey","family":"Thomas\u2010Schoemann","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Cochin Hospital, AP\u2010HP, University of Paris  Paris France"},{"name":"Department of Medical Oncology Cochin Hospital, AP\u2010HP, Universit\u00e9 de Paris  Paris France"},{"name":"UMR8038 CNRS, U.1268 INSERM, Faculty of Pharmacy University Paris Descartes, PRES Sorbonne Paris Cit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21403"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.079038"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1021685"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010014\u20100137\u20102"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010019\u20100716\u20108"},{"key":"e_1_2_10_7_1","unstructured":"Pfizer.Xalkori (crizotinib) 250 mg hard capsules Summary of product characteristics (SmPC). Pfizer Europe MA EEIG Belgium (2012 rev 23\/10\/2018)."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.47"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010019\u201000774\u20100"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283385a1c"},{"issue":"21","key":"e_1_2_10_12_1","first-page":"1044","article-title":"Assessment of antihypertensive compliance using a self\u2010administered questionnaire: development and use in a hypertension clinic","volume":"30","author":"Girerd X","year":"2001","journal-title":"Presse Med"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010015\u20100334\u20107"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1105083"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00034"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15674","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:16:13Z","timestamp":1692648973000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/bcp.15674"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15674","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]}}}